Price alert —
Sign in to get a one-time email the moment ABBV crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · ABBV
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $15.0B | $0.7B | $4.7B | $3.6B | 4.6% | 31.6% |
| 2025-12-31 | $16.6B | $1.8B | $5.8B | $4.9B | 10.9% | 35.0% |
| 2025-09-30 | $15.8B | $0.2B | $4.6B | $6.6B | 1.2% | 29.1% |
| 2025-06-30 | $15.4B | $0.9B | $5.7B | $4.9B | 6.1% | 37.1% |
| 2025-03-31 | $13.3B | $1.3B | $4.0B | $1.4B | 9.6% | 29.8% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare ABBV vs peers
Line ABBV up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with ABBV
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-04-29 | 2.65 | 2.67 | -0.8% | +3.6% |
| 2026-02-04 | 2.71 | 2.65 | +2.2% | +0.9% |
| 2025-10-31 | 1.86 | 1.78 | +4.2% | -2.8% |
| 2025-07-31 | 2.97 | 2.91 | +2.1% | +3.3% |
| 2025-04-25 | 2.46 | 2.40 | +2.6% | +3.4% |
| 2025-01-31 | 2.16 | 2.12 | +1.9% | +3.4% |
| 2024-10-30 | 3.00 | 2.92 | +2.8% | +1.2% |
| 2024-07-25 | 2.65 | 2.66 | -0.4% | +1.6% |
| 2024-04-26 | 2.31 | 2.26 | +2.4% | +1.2% |
| 2024-02-02 | 2.79 | 2.80 | -0.3% | +1.5% |
| 2023-10-27 | 2.95 | 2.87 | +2.8% | +2.1% |
| 2023-07-27 | 2.91 | 2.81 | +3.6% | +1.3% |
| 2023-04-27 | 2.46 | 2.49 | -1.4% | +1.5% |
| 2023-02-09 | 3.60 | 3.58 | +0.7% | +2.2% |
| 2022-10-28 | 3.66 | 3.57 | +2.6% | -0.8% |
| 2022-07-29 | 3.37 | 3.31 | +1.8% | -2.3% |
| 2022-04-29 | 3.16 | 3.14 | +0.6% | +0.7% |
| 2022-02-02 | 3.31 | 3.28 | +0.8% | +1.5% |
| 2021-10-29 | 3.33 | 3.22 | +3.5% | +0.1% |
| 2021-07-30 | 3.11 | 3.03 | +2.6% | -0.7% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV ★ | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
| ABT | $175B | 28.2 | 16.6 | 3.8 | 17.1 | 3.4 | 56.8% | 13.0% | -47.5% | — |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 34.79%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 150,698,125 | 8.53% |
| Vanguard Capital Management LLC | 114,880,324 | 6.50% |
| State Street Corporation | 81,217,516 | 4.60% |
| JPMORGAN CHASE & CO | 56,741,691 | 3.21% |
| Vanguard Portfolio Management LLC | 49,523,078 | 2.80% |
| Geode Capital Management, LLC | 46,737,581 | 2.65% |
| Morgan Stanley | 38,016,774 | 2.15% |
| Capital Research Global Investors | 31,254,786 | 1.77% |
| Bank of America Corporation | 23,936,943 | 1.35% |
| FMR, LLC | 21,762,703 | 1.23% |
Insider activity · 90d
13 buys / 0 sells · ratio 13.0 · Finnhub
- Quaggin Susan E BUY 853 @ $251.64
- RAPP EDWARD J BUY 29,236 @ $251.64
- Quaggin Susan E BUY 3,643
- Davis Jennifer L. BUY 3,643
- MEYER MELODY B BUY 17,616
- BURNSIDE WILLIAM H.L. BUY 28,076
- Hart Brett J BUY 20,590
- Roberts Rebecca B BUY 14,846
- FREYMAN THOMAS C BUY 127,869
- WADDELL FREDERICK H BUY 30,076
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-06 | 8-K | view · |
| 4 | 2026-07-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-07-02 | Insider transaction (Form 4) | view · |
| 8-K | 2026-06-22 | FORM 8-K | view · |
| 8-K | 2026-05-12 | FORM 8-K | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 10-Q | 2026-05-08 | 10-Q | view · |
| 8-K | 2026-04-29 | 8-K | view · |
| 8-K | 2026-04-03 | 8-K | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| DEF 14A | 2026-03-23 | DEF 14A | view · |
| 4 | 2026-03-06 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-06 | Insider transaction (Form 4) | view · |
| 8-K | 2026-03-04 | FORM 8-K | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-27 | Insider transaction (Form 4) | view · |
| 8-K | 2026-02-26 | FORM 8-K | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-20 | Insider transaction (Form 4) | view · |
| 10-K | 2026-02-20 | 10-K | view · |
| 8-K | 2026-02-04 | 8-K | view · |
| 8-K | 2026-01-07 | 8-K | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 10-Q | 2025-11-04 | 10-Q | view · |
| 8-K | 2025-10-31 | 8-K | view · |
| 8-K | 2025-10-03 | 8-K | view · |
| 4 | 2025-10-02 | Insider transaction (Form 4) | view · |
| 4 | 2025-10-02 | Insider transaction (Form 4) | view · |
| 4 | 2025-10-02 | Insider transaction (Form 4) | view · |
| 8-K | 2025-09-11 | FORM 8-K | view · |
| 4 | 2025-08-14 | Insider transaction (Form 4) | view · |
| 4 | 2025-08-07 | Insider transaction (Form 4) | view · |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozur…
Options picks · ABBV
ITM + OTM ideas from the latest scanLoading…
Congress trades · ABBV
STOCK Act disclosuresLoading…
SEC filings & insiders · ABBV
EDGAR · liveLoading…
Holders · ABBV
Institutions & insider activityLoading…